Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026

• Vivos Therapeutics filed an 8-K/A to correct the “Date of Report” in its Sept. 4 Form 8-K.
• The filing changes the date to Sept. 2, 2026 from Aug. 31, 2026 for transactions under Items 1.01 and 3.02.
• The corrected disclosure ties to exchanges with Streeterville Capital, converting $2.86 million of note principal into up to 11,445,080 shares.
• These exchanges were consummated on Sept. 2, 2026; the remaining Streeterville Note principal balance was $3.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-041807), on September 08, 2026, and is solely responsible for the information contained therein.